

Issue

Methotrexate is an antimetabolite, primarily used orally **once weekly** in the treatment of rheumatoid arthritis, psoriasis and Crohn's disease. Methotrexate is a high-risk drug, i.e. serious patient harm can occur as a result of errors involving incorrect frequency (daily rather than once weekly), incorrect strength tablets, incorrect strength tablets, or from an adverse drug reaction. Care must be taken with methotrexate use at all stages of medication use, including at transitions of care. (Note this alert does not cover the use of methotrexate in haematology or oncology.)

Evidence of Harm

Numerous adverse events have occurred worldwide as a result of preventable errors. Some examples include:

- A hospital in-patient received 15mg methotrexate orally daily instead of the intended weekly dose for 8 days, resulting in death from bronchial pneumonia as a consequence of bone marrow suppression caused by methotrexate toxicity. (Ireland)(1)
- A patient was prescribed, dispensed and administered methotrexate 10mg orally daily, instead of the intended once weekly dose in community and in hospital. The patient died. (UK)(2)
- A GP prescribed a daily dose of oral methotrexate for a flare-up of psoriasis. The pharmacist queried the dose but was reassured it was correct and despite concerns dispensed the prescription. Patient subsequently died of complications of methotrexate toxicity. (Australia)(3)

How to Reduce the Risks in hospitals

- Keep only one strength of oral methotrexate (2.5mg) in stock.
- Prescribe, dispense and administer oral methotrexate **ONCE WEEKLY** (usual dose range 7.5mg – 25mg orally once weekly), specifying the day of the week.
- Specify the number of tablets ("10mg, i.e. 4 x 2.5mg tablets") to be taken per dose.
- **Ensure that the patient understands their therapy, including dose and frequency, when and where monitoring will be carried out, the signs and symptoms of toxicity and what to do if they occur. Provide written information to patients.**
- Folic acid 5mg once weekly orally is indicated to reduce mucositis and gastrointestinal side effects. It should be administered on a different day of the week to methotrexate(4).
- Be aware of methotrexate contra-indications and cautions, symptoms of adverse reactions and toxicity, the appropriate monitoring to carry out and potential interactions with other drugs, e.g. NSAIDs as they can reduce renal function and thus decrease the clearance of methotrexate(5).
- Write the drug name in full: never abbreviate.
- In hospitals, the Drug Chart should clearly indicate which day methotrexate is due. Cross out the remaining days on the prescription as shown:

DRUG (APPROVED NAME)	DOSE	START DATE	STOP DATE																
METHOTREXATE	15mg	06:00	06:00	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
FREQUENCY	ROUTE	START DATE	STOP DATE																
ONCE WEEKLY	P	26/7/18	10:00																
PREScriBER'S SIGNATURE	CLINICAL REVIEW																		
A. Doctor																			
PHARMACY																			
ON TUESDAYS	(6 x 2.5mg tabs)																		

- Configure electronic prescribing and administration systems for safety e.g. to prevent daily prescribing and administration, appropriate use of warnings, optimise use of barcode scanning to prevent strength mis-selection.
- Specify full directions on the label where possible.
- Where feasible, all patients should receive education but if not possible, patients should be prioritised for education/counselling prior to discharge, particularly where the methotrexate is new or there has been a dose change in hospital.
- Highlight the importance of dispensing the correct strength and once weekly dosing on dispensing systems and in the methotrexate storage area.
- Remove methotrexate from ward stock, dispense one dose only at a time.

Further information

Product information on www.hpra.ie; www.medicines.ie or other reliable references, e.g. BNF(6).

Methotrexate guidance available at: www.thepsi.ie(7); www.ismp.org(8); <http://www.ipnsm.hscni.net/methotrexate-oral-shared-care-guideline/> (9)

References:

1. Kelleher O. Patient (74) died after ward dosage mix-up [Internet]. The Irish Times. 2001 [cited 2021 Apr 23]. Available from: <https://www.irishtimes.com/news/patient-74-die-after-r-ward-dosage-mix-up-1.341702>
2. Cambridgeshire Health Authority. Methotrexate Toxicity - An inquiry into the death of a Cambridgeshire patient in April 2000 [Internet]. 2000 Jul. Available from: <http://anthonycox.org/wp-content/uploads/2012/12/methotrexate-toxicity.pdf>
3. Minter/Ellison. Inquest into the Death of Ian John Gilbert - Case Summary [Internet]. [cited 2021 Apr 23]. Available from: <https://www.minterellison.com/articles/inquest-into-the-death-of-ian-john-gilbert>
4. ISMP. Oral methotrexate (to treat conditions other than cancer) [Internet]. 2018. Available from: <https://www.ismp.org/sites/default/files/attachments/2018-11/MethotrexateFinal.pdf>
5. Preston CL, Stockley IH. Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management. London [etc.]: Pharmaceutical Press; 2019.
6. Joint Formulary Committee (Great Britain). BNF 81: March 2021. 2021.
7. PSI. Guidance for Pharmacists on Safe Supply of Oral Methotrexate [Internet]. 2015. Available from: https://www.thepsi.ie/Libraries/Folder_Pharmacy_Practice_Guidance/PPGF_03_3_Safe_supply_of_Methotrexate.sfb.asbx
8. ISMP. Call to Action: Longstanding Strategies to Prevent Accidental Daily Methotrexate Dosing Must Be Implemented [Internet]. Institute For Safe Medication Practices. 2018 [cited 2021 Apr 23]. Available from: <https://www.ismp.org/resources/call-action-longstanding-strategies-to-prevent-accidental-daily-methotrexate-dosing-must-be-implemented>
9. Snapshot [Internet]. [cited 2021 Apr 23]. Available from: <http://www.ipnsm.hscni.net/methotrexate-oral-shared-care-guideline/>

Prepared by:

©IMSN. The IMSN allows the sharing or reproduction of this material, provided that the source of the information is appropriately acknowledged and a link to our website is supplied. It is recommended that you also refer to www.imsn.ie as the document may have been updated since this was accessed.

IMSN makes no representation, express or implied, regarding the accuracy of this information and cannot accept any legal responsibility for any errors or omissions that may be made.

Website: www.imsn.ie

Email: enquiries@imsn.ie

Version 2 May 2021